SciBase invitation to a webinar on November 10 at 11:00 CET
STOCKHOLM, SWEDEN - November 8, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to invite investors, analysts and media to a webinar on November 10 at CET 11.00 – 12.00. The event will only be digital.
The focus will be on SciBase’s recently announced collaboration with Johnson & Johnson Consumer Health to develop a unique AI-based screening tool to predict the development of a common type of eczema known as atopic dermatitis in infants. SciBase CEO Simon Grant will give an in-depth picture of the potential that exists in the skin barrier segment as well as a general update.
Link to the webinar: https://us06web.zoom.us/webinar/register/WN__tjnmigWSDeqGmY4LYbnRg
Agenda for the webinar:
- Introduction by CEO Simon Grant
- Background around skin barrier from Professor Cezmi Akdis
- Presentation by CEO Simon Grant
The webinar will be held in English. Participants will be given the opportunity to ask questions during the event via chat. Questions can also be submitted in advance to [email protected]
A recorded version of the webinar will be available on the SciBase website afterwards.
For more information around skin barrier and SciBase: https://barrier.scibase.com/
For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
Certified Advisor (CA):
Tel: +46 8 580 065 99
Email: [email protected]
About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
Gabather AB (publ) meddelar sista dag för handel med BTA
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL STORBRITANNIEN, USA, KANADA, JAPAN AUSTRALIEN, HONGKONG, NYA ZEELAND, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS, SCHWEIZ, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIO...
BioStock: Chordate’s CEO on entering new markets
How does Chordate Medical’s treatment for rhinitis and chronic migraine work? What market interest has the company seen and what strategy is it working with to gain market share? In connection with the BioStock Investor Meeting, the company’s CEO Anders Weilandt talked about this, among...
BioStock: Chordates vd om inträdet på nya marknader
Hur fungerar Chordate Medicals behandling för rinit och kronisk migrän? Vad har bolaget sett för marknadsintresse och vilken strategi jobbar man med för att ta marknadsandelar?I samband med BioStock Investor Meeting berättade bolagets vd Anders Weilandt mer om bland an...
Nightingale Health Plc: Unaudited financial information in accordance with IFRS for the comparative half-year periods
Nightingale Health Plc ("Nightingale Health" or the "Company") published on 27 October 2022 its first consolidated financial statements prepared in accordance with IFRS for the financial year ended 30 June 2022. Before publishing the consolidated financial statements Nightingale...